Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $77.00

Ionis Pharmaceuticals (NASDAQ:IONS) had its target price boosted by Stifel Nicolaus from $73.00 to $77.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a hold rating on the stock.

Several other equities research analysts have also recently issued reports on IONS. Piper Sandler lifted their target price on shares of Ionis Pharmaceuticals from $77.00 to $87.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Morgan Stanley set a $95.00 price target on shares of Ionis Pharmaceuticals and gave the stock an “overweight” rating in a research note on Wednesday. Barclays assumed coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $95.00 price target on the stock. Raymond James Financial reiterated a “strong-buy” rating and issued a $89.00 price objective (up from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. Finally, TD Cowen restated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.80.

Ionis Pharmaceuticals Trading Up 0.7%

IONS stock opened at $81.15 on Thursday. Ionis Pharmaceuticals has a 12-month low of $23.95 and a 12-month high of $86.74. The business’s 50-day moving average is $81.33 and its 200 day moving average is $72.12. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The stock has a market cap of $13.14 billion, a price-to-earnings ratio of -33.26 and a beta of 0.29.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, February 25th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.18). The firm had revenue of $203.00 million during the quarter, compared to analysts’ expectations of $156.07 million. Ionis Pharmaceuticals had a negative net margin of 40.36% and a negative return on equity of 66.25%. The business’s revenue was down 10.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.66) EPS. On average, sell-side analysts anticipate that Ionis Pharmaceuticals will post -3.5 EPS for the current fiscal year.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Joseph H. Wender sold 28,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, December 1st. The stock was sold at an average price of $80.82, for a total value of $2,262,960.00. Following the sale, the director owned 36,035 shares in the company, valued at $2,912,348.70. The trade was a 43.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP C Frank Bennett sold 85,089 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $82.93, for a total value of $7,056,430.77. Following the transaction, the executive vice president owned 80,293 shares of the company’s stock, valued at approximately $6,658,698.49. This represents a 51.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 464,579 shares of company stock valued at $37,630,193 in the last ninety days. 2.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IONS. Axxcess Wealth Management LLC acquired a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $228,000. Corient Private Wealth LLC lifted its holdings in shares of Ionis Pharmaceuticals by 3,161.5% in the 4th quarter. Corient Private Wealth LLC now owns 214,936 shares of the company’s stock worth $17,004,000 after acquiring an additional 208,346 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in shares of Ionis Pharmaceuticals by 48.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 5,554 shares of the company’s stock worth $439,000 after purchasing an additional 1,807 shares during the period. Mackenzie Financial Corp increased its holdings in Ionis Pharmaceuticals by 8.4% in the 4th quarter. Mackenzie Financial Corp now owns 3,891 shares of the company’s stock valued at $307,000 after purchasing an additional 303 shares during the last quarter. Finally, ADAR1 Capital Management LLC increased its holdings in Ionis Pharmaceuticals by 9.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 147,130 shares of the company’s stock valued at $11,639,000 after purchasing an additional 13,312 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

More Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Piper Sandler raised its price target to $100 and moved to an “overweight” rating, signaling ~23% upside from current levels — a clear buy-side endorsement. Article Title
• Positive Sentiment: Needham lifted its price target to $103 from $90, another analyst upgrade supporting the rally and reflecting greater confidence in revenue trajectory. Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
• Positive Sentiment: Updates to Tryngolza outlook are materially positive: recent analysis lifts peak revenue estimates (several sources cite >$2B for Tryngolza and company-level peak revenue/royalty/milestone potential in the multi‑billion range), and management guides to cash-flow breakeven by 2028 — bullish for long-term value. Ionis Pharmaceuticals: Digesting Recent Events
• Neutral Sentiment: Company presented at Oppenheimer’s healthcare conference; slides/transcript provide additional visibility into pipeline progress and commercialization strategy but are informational rather than catalytic. IONS Presents at Oppenheimer Conference Transcript
• Neutral Sentiment: General earnings call coverage/recaps are available for detail on management commentary and guidance; useful for modeling but not single-handedly market-moving. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 results were mixed: revenue and Tryngolza sales beat expectations, but EPS missed estimates and management gave a softer 2026 outlook, which pressured the stock in after-hours/early trade. Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
• Negative Sentiment: Coverage noted the EPS miss led to a gap-down reaction in some sessions; near-term uptake for new drugs and the FY2026 revenue cadence remain the main risk factors to watch. Shares Gap Down on Disappointing Earnings
• Negative Sentiment: Stifel raised its target modestly to $77 but kept a “hold” rating — the lower relative PT signals at least one shop sees limited near-term upside. Article Title

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.